Physician profile
Mark J Silver
NPI 1740486398
$2,124.22
in general payments reported to CMS, 2019-2025
12 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $393 · 2020: $22.73 · 2021: $973 · 2022: $18.94 · 2023: $287 · 2024: $219 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $716.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $716.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $1,181.96 | 2019-2024 | Yupelri |
| Boston Scientific Corporation | $239.70 | 2019-2022 | |
| Inari Medical, INC. | $138.00 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $124.30 | 2025 | |
| Penumbra, INC. | $117.31 | 2023 | Indigo System |
| Genzyme Corporation | $94.35 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $74.62 | 2023-2025 | Lifevest |
| Paratek Pharmaceuticals, INC. | $53.45 | 2024-2025 | Nuzyra |
| E.R. Squibb & Sons, L.L.C. | $32.22 | 2019 | |
| Merck Sharp & Dohme LLC | $25.93 | 2019-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $22.73 | 2020 | |
| Alexion Pharmaceuticals, INC. | $19.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.